Male Apoe -/-mice were injected IP with TRAF-STOP 6877002 (n=13 and n=12), TRAF-STOP 6860766 (n= 12 and n= 11) at 10 mol/kg/day, or vehicle (PBS, 0.05% Tween 80, 5% DMSO) (n=15 and n=11) for 6 weeks, starting at the age of 12 or 22 weeks, and were fed a normal chow diet throughout the experiment. Mice were then sacrificed and the arterial tree was perfused. The aortic arch and its main branch points were excised, fixed overnight, and embedded in paraffin.
Fasting insulin levels (Mercodia), AST (Biomatik), ALT (Biomatik), leptin (Crystalchem) and adiponectin (Assaypro) were determined by ELISA. Fasting glucose levels were determined by a Glucose Assay Kit (Abcam) according to the manufacturer's protocol. The homeostasis model assessment of insulin resistance was calculated. ELISA was used to determine the plasma levels of IgM (Bender MedSystems), IgG (Bender MedSystems), and anti-MOG IgG (AnaSpec).
Intravital microscopy
Intravital microscopy of the carotid artery was performed in Cx3cr1egfp/Apoe -/-mice (n=5 vehicle, n=7 6877002, n=8 6860766) that were fed a 0.15% cholesterol diet for 6 weeks as previously described (1) . Mice received a single IP injection of the TRAF-STOP or vehicle. A PE-conjugated antibody to Ly6G (1A8, 1 µg) was instilled via a jugular vein catheter 5 minutes prior to recording. After recording of neutrophil and monocyte adhesion, rhodamine 6G was administered to visualize all adherent leukocytes. Intravital microscopy was performed using an Olympus BX51 microscope equipped with a beam splitter to enable synchronized dual-channel recording, a Hamamatsu 9100-02 EMCCD camera, and a 10x saline-immersion objective.
Olympus cell software was used for image acquisition and analysis.
Two-photon laser scanning microcopy of whole-mount carotid arteries
6-8 weeks old Apoe -/-mice received a 0.15% cholesterol diet for 6 weeks. Carotid arteries were explanted and treated with TRAF STOP 6877002 (10 µmol/L) or control. Treated vessels were mounted on glass micropipettes in a home built arteriography chamber. CD31 and VCAM-1 expression were analyzed using CD31 (eBioscience) and VCAM-1 (Biolegend) antibodies. The mounted carotid arteries were visualized using a LeicaSP5IIMP two-photon laser scanning microscope with a pre-chirped and pulsed Ti:Sapphire Laser (Spectra Physics MaiTai Deepsee)
tuned at 800nm and a 20×NA1.00 (Leica) water dipping objective. Image acquisition, processing, and quantification were performed using LasX software including the 3D analysis package (Leica). by the agonistic CD40 antibody FGK45 (25 µg/ml, Bioceros BV) for 6 hours. CCL-2 was determined by ELISA (eBioscience) according to the manufacture's protocol.
In vitro bone marrow derived macrophages

Quantitative PCR
RNA was isolated from BM-derived macrophages, THP1 cells, Jurkat cells, CA46 cells, HUVECs and reverse transcribed using an iScript cDNA synthesis kit (Bio-Rad). Quantitative (q)PCR was performed with a SYBR Green PCR kit (Applied Biosystems) on a ViiA 7 real-time PCR system (Applied Biosystems). Primer sequences are available upon request.
Migration assay
Human blood monocytes were isolated from buffy coats of healthy donors by Ficoll gradient and CD14-coated beads. The procedure was approved by the local human experimental committee.
The human endothelial cell (EC) line hCMEC/D3 was grown in endothelial cell basal medium-2 supplemented with hEGF, hydrocortisone, GA-1000, FBS, VEGF, hFGF-B, R3-IGF-1, ascorbic acid and 2.5 % fetal calf serum (EGM-2). hCMEC/D3 cells were grown to confluence in 96-well plates. Monocytes or EC were incubated with the vehicle or 6877002 or 6860766 at 10 µM for 1 hour, after which a CD40 stimulating antibody was added at 30 µg/ml for 10-12 hours (G28.5, Bioceros, Utrecht, the Netherlands). After extensive washing, monocytes (7.5 10 5 cells/ml) were added to EC monolayers and the number of migrated monocytes was assessed after 4 hours.
Migrated cells were quantified by counting per field-of-view. From one experiment, five fields were analyzed. Movies were generated using VirtualDub.
Chemotaxis assay
Chemotaxis of macrophages was assessed using 24-well Transwell migration chambers (Costar;
Corning) with a pore size of 5 µm. BM-derived macrophages (5 × 10 4 ) were treated with TRAF-STOP or vehicle and FGK-45 or isotype control (as described above) and added to the chamber.
Complete medium, including 100 ng/ml CCL2 (R&D Systems), was added to the lower chambers and migration was performed at 37°C for 4 hours. Non-migrated cells were removed from the membranes, and migrated cells were fixed with PFA and stained with toluidine blue.
Membranes were cut out of inserts and mounted onto slides in immersion oil. The number of migrated cells was counted on five randomly chosen fields of each membrane.
In vitro lipid uptake, phagocytosis and efferocytosis
BMDMs were obtained as described above. BMDMs were treated with TRAF-STOPs and subsequently activated with the agonistic CD40 antibody FGK45 (25 µg/ml, Bioceros BV) for 6
hours. After 24 hours, BMDMs were labeled with CD36-APC (BioLegend) and expression was analyzed using flowcytometry. Oil Red O staining (0.3% in 60% isopropanol, Sigma) was performed to determine lipid accumulation. For phagocytosis experiments, fluorescently labeled latex beads were incubated with the BMDMs, as described above, and uptake was analyzed by flowcytometry. For oxLDL uptake studies, TRAF-STOP-treated BMDMs were incubated with 12.5 μg/ml Dil-oxLDL (Sanbio, Uden, The Netherlands) for 6 hours. Uptake was assessed by flow cytometry after residual DiI-oxLDL was washed away and expressed as mean fluorescent intensity. For efferocytosis studies, BMDMs were fluorescently labeled using Celltrace CSFE Cell Proliferation Kit (Invitrogen) according to manufacturer's instructions. Next, apoptosis was induced by adding hydrogen peroxide. After 24 hours, the cells were washed and the apoptotic cells were added to the TRAF-STOP treated BMDMs. After 6 hours, uptake of apoptotic cells was analyzed by flowcytometry.
Cell cultures
THP-1, Jurkat and CA46 cells were cultured in RPMI1640 medium (Invitrogen) containing 10% FCS, Glutamate, and penicillin/streptavidin. HUVECs were cultured in M199 (GIBCO Invitrogen) with 100 U/ml Penicillin/Streptomycin (P/S), 20% heat-inactivated FCS, 0.05μg/ml of heparin (Sigma), 2mM L-Glutamine (Invitrogen) and 25μg/ml Endothelial Cell Growth Supplement (ECGS, Sigma). HUVECs were used between passage 1 and 3 for experiments.
THP-1 cells were differentiated into macrophages by 48 hours PMA (50g/mL) stimulation.
After 1 hour incubation with TRAF-STOP 6877002, 6860766 or vehicle, THP-1 cells were activated with LPS (10 ng/mL), Jurkat cells were activated with CD3/CD28 Dynabeads (ThermoFisher), CA46 cells with the agonistic G28.5 (10 g/mL) CD40 antibody (Bioceros) and R848 (2.5 g/mL), HUVECs with G28.5 (10 g/mL) and TNF (10 ng/mL) for 6 hours. After the experimental procedure, cells were lysed and RNA was isolated.
Western blot
BMDMs were cultured as described above and incubated with vehicle of TRAF-STOP at 10 µM 1 hour our prior to stimulation with FGK45 (30 ug/ml, Bioceros BV). BMDM were stimulated for 10 minutes or 24 hours and subsequently lysed in RIPA lysis buffer. Protein concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Scientific). Equal amounts of protein samples were loaded on a SDS polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad). After blocking with 5% BSA in PBS containing 0.05% Tween-20, blots
were incubated overnight with the indicated antibodies; pTAK, NF-κBp65, pNF-κBp65
αTubulin, β-actin and NF-κB2 antibodies were from Cell Signaling Technology, pERK and ERK antibodies were from Santa Cruz. Blots were then washed and incubated with the appropriate HRP-conjugated secondary antibody (1:5000; DAKO) and visualized using the ECL substrate kit (Thermo Scientific).
Transcriptomics
BMDMs of C57Bl6 mice (n=3) were pre-incubated with vehicle or TRAF-STOP for 1 hour and subsequently activated by the agonistic CD40 antibody FGK45 (25 µg/ml, Bioceros BV) for 8
hours. RNA was isolated using the Aurum total RNA isolation kit (Bio-Rad) and samples were sent to ServiceXS for further microarray processing. In brief, to assess the quality of the samples, the concentration of the RNA was determined using the Nanodrop ND1000 spectrophotometer. 
Microarray pre-processing and data analysis
Analyses were carried out with Bioconductor packages in the statistical software package R (version 3.1.3). Normexp-by-control background correction, quantile normalization, and log2 transformation were performed on the Illumina sample and control probe profiles using the limma package (version 3.22.7). The arrayQualityMetrics package (version 3.22.1) was used to assess whether the microarray data were of good quality. Only probes detected (detection p-value < 0.05) on at least one array were included in the differential expression analysis. Gene-wise linear models were fitted using the limma package. Differential expression between the different conditions was assessed via a moderated t-test. The illuminaMousev2.db package (version 1.24.0) was used to update the probe annotation provided by Illumina. The data set with differentially expressed genes (nominal p-value<0.05) was analyzed using Ingenuity Pathway Analysis (IPA, Ingenuity Systems) to test for enriched canonical pathways and networks. The background set for the gene enrichment analyses consisted of all genes that were detected on at least one array. Significance of enrichment was calculated using a right-tailed Fisher's Exact
Test and the resulting p-values were corrected for multiple testing using the Benjamini-Hochberg false discovery rate. The microarray data have been deposited in NCBI Gene Expression
Omnibus in a MIAME compliant format and are accessible under GEO Series accession number
Docking Simulations
Molecular docking simulations of ligand binding to the TRAF6 C-domain were performed using Autodock Vina and binding modes were visualized and analyzed using PyMOL 
TRAF6 C-domain mutants: expression, purification and binding analyses
The TRAF6 C-domain (residues 346-504) was carboxy-terminally His-tagged by cloning into the pET21d expression vector (Novagen). Mutants of the TRAF6 C-domain were generated by site-directed mutagenesis using the QuickChange site-directed mutagenesis method (Stratagene) according to the manufacturer's instruction. The primers used to generate the mutants are listed in Suppl. Table 3 . All constructs were verified by sequencing. Recombinant TRAF6 C-domain and its mutants were overexpressed in E. coli BL21 (DE3) and affinity-purified using a Ni-NTA column mounted on an NGC medium pressure chromatography system (Bio-Rad). Bound protein was eluted using an imidazole gradient and the buffer was exchanged to 10 mM Hepes, pH 7.4, 150 mM NaCl and 5 mM 2-mercaptoethanol using a Bio-Gel P-6 column (Bio-Rad). The direct binding between the TRAF6 C-domain and the 6877002 and 6860766 compounds was measured via SPR (Biacore T200, GE Healthcare). TRAF6 C-domains were immobilized on HC1500M Sensor Chips using the amine coupling method. This reached a density of approximately 37,000 RU. Compounds were dissolved in SPR running buffer (PBS, 0.05% Tween-20, 5% DMSO, pH 7.4). All measurements were carried out at 25 o C and with a flow rate of 50 µl min -1 in SPR running buffer. Sensorgrams were corrected by subtraction of the level of SPR signal observed on the empty reference flow channel during injection of the compounds.
Data were analyzed using the BIAevaluation software. Equilibrium dissociation constants (K D ) were determined from a model of the steady state affinity (at least 2 independent runs performed in duplicate were averaged).
Experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) was induced in 10-week-old female C57BL/6 mice (n=11-12 per group) and immunoglobulin levels were determined, as described 
DC-OTII co-cultures
Bone marrow cells derived from femur and tibia of C57Bl6 mice were cultured for 10 days in IMDM supplemented with 9% FBS, 100 U/ml Pen/Strep (GE Healthcare Life Sciences), 2mM
Glutamin (Thermo Fisher) and 20 µM beta-mercaptoethanol (Sigma Aldrich) and 20 ng/ml GMCSF (Peprotech) at 37C and 5% CO2. 50.000 DC were plated in 96 well plates (Greiner) and pre-treated for 1 hour with 10 µM compound or vehicle. Splenic CD4 T-cells from OT-II transgenic mice were purified using negative selection according to the manufacturers' instructions (Magnisort, ebioscience) and labelled with CFSE (1 µM, 10 min, Invitrogen).
DC and OT-II were co-cultured in a 1:2 ratio with or without 1 µg/ml OVA323 (ISQAVHAAHAEINEAGR, Genscript). After 96 hours cells were collected and stained with anti-CD4-efluor450, anti-CD25-APC and anti-Thy1.2-Pe/Cy7 (all Thermofisher) and analysed with flowcytometry (CytoFlex, Beckman Coulter).
Peritonitis
E. coli peritonitis was induced in male C57BL/6 mice (n=8 per group) and bacterial outgrowth was analyzed. E. coli O18:K1 was cultured in Luria-Bertani medium (Difco) at 37 °C to midlog phase and washed twice with pyrogen-free sterile 0.9% NaCl (Baxter), as previously described starting 3 hours before and 6 and 12 hours after induction of perotinitis. The animals were sacrificed 16 hours after induction of peritonitis using inhalation anesthesia with isoflurane.
Peritoneal lavage was performed with 5 ml of sterile phosphate-buffered saline, blood was isolated via cardiac puncture. Liver lobes and lungs were isolated and homogenized in PBS using a tissue homogenizer (Biospec Products). Bacterial loads in peritoneal lavage fluid, blood, and tissue homogenates were determined by plating serial dilutions of each sample on blood agar plates overnight at 37 °C and counting the number of cfu.
Synthesis of rHDL based nanoparticles
The synthesis of rHDL-6877002 was based on a previously published method (3). In short, the CD40-TRAF6 inhibitor 6877002 was combined with 1-myristoyl-2-hydroxy-sn-glycerophosphocholine (MHPC) and 1, 2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) (Avanti Polar Lipids) in chloroform/methanol mixture (9:1 by volume) and then dried in a vacuum, creating a thin lipid film. Human apolipoprotein A1 (apoA-I) was dissolved in PBS and added to the lipid film. The apoA-I was left to incubate at 37°C for 1 hour or until the film was hydrated and a homogenous solution was formed. The solution was then sonicated for 20 minutes to form rHDL-6877002 nanoparticles. Subsequently, the solution was purified by multiple centrifugation and filtration steps. In targeting, imaging and biodistribution experiments, the components for rHDL-6877002 were combined with DiR or DiO (Invitrogen)
to allow for incorporation of the labels.
Ex vivo near infrared fluorescence imaging (NIRF)
Female Apoe -/-mice fed a high-fat diet for 12 weeks, received a single IV injection with DiR (0.5 mg/kg) labeled rHDL-6877002 (10mol/kg, n=3) or saline (n=1). Mice were sacrificed 24 hours after the injection and perfused with 60 mL PBS. Liver, spleen, lung, kidneys, heart and muscle tissue were collected for NIRF imaging. Fluorescent images were acquired with the IVIS 200 system (Xenogen), with a 2 second exposure time, using a 745 nm excitation filter and a 820 nm emission filter.
Statistics
Data are presented as mean ± SEM. Data were analyzed by using either an unpaired Student's t test, a Bonferoni-corrected Student's t test, or an ANOVA as indicated, using the GraphPad Prism 5.0 software (GraphPad Software, Inc.). P-values <0.05 were considered significant. immunohistochemistry and sirius red staining revealed no inflammation or fibrosis in the liver (scale bar 100 m) (G). ALT and AST levels were not affected by rHDL-6877002 treatment (H).
Analysis of splenic leukocyte subsets by flow cytometry revealed no abnormalities and rHDL-
